Literature DB >> 15314639

Abnormalities of apoptotic and cell cycle regulatory proteins in distinct histopathologic components of benign prostatic hyperplasia.

R Gandour-Edwards1, P C Mack, R W Devere-White, P H Gumerlock.   

Abstract

INTRODUCTION: Benign prostatic hyperplasia (BPH) is a slowly progressive abnormal glandular enlargement with heterogeneous morphology. Disruption of apoptotic pathways has been suggested as an important regulatory mechanism in this common and significantly morbid disease.
METHODS: Prostatic tissue from 20 patients with BPH and no prior or subsequent prostatic carcinoma was obtained by transurethral prostatectomy (TURP) at the University of California Davis. Apoptotic regulatory proteins: BCL2, BAX and p27 were analyzed by immunohistochemistry and evaluated for expression in four distinct histologic patterns: hyperplastic epithelium, nodules, dilated glands and atrophic/inflammatory glands.
RESULTS: Particularly striking was the decreased expression of BAX and an abnormal BCL2 : BAX ratio within all nodules relative to expression in other epithelial patterns. p27 expression was decreased in 35% of the hyperplastic epithelial areas and 10% of the nodules. DISCUSSION: Overall, abnormal expression of BCL2, BAX and/or p27 was identified in the hyperplastic epithelium of 19 (90%) of specimens and all 12 (100%) of the hyperplastic nodules. The high frequency of abnormalities in apoptosis regulatory genes, suggests that alteration of apoptotic pathways is important for the development of this condition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15314639     DOI: 10.1038/sj.pcan.4500749

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  5 in total

1.  Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model.

Authors:  Alexander D Borowsky; Karen H Dingley; Esther Ubick; Kenneth W Turteltaub; Robert D Cardiff; Ralph Devere-White
Journal:  Neoplasia       Date:  2006-09       Impact factor: 5.715

2.  A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.

Authors:  Peter J Van Veldhuizen; Michael Hussey; Primo N Lara; Philip C Mack; Regina Gandour-Edwards; Joseph I Clark; Marianne K Lange; David E Crawford
Journal:  Am J Clin Oncol       Date:  2009-10       Impact factor: 2.339

3.  Expression of p27((Kip1)), cyclin D3 and Ki67 in BPH, prostate cancer and hormone-treated prostate cancer cells.

Authors:  David Nikoleishvili; Ambrosi Pertia; Omar Trsintsadze; Nino Gogokhia; Laurent Managadze; Archil Chkhotua
Journal:  Int Urol Nephrol       Date:  2008-03-04       Impact factor: 2.370

4.  Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line.

Authors:  David A Davis; Sarah H Sarkar; Maha Hussain; Yiwei Li; Fazlul H Sarkar
Journal:  BMC Cancer       Date:  2006-01-24       Impact factor: 4.430

Review 5.  Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies.

Authors:  Giuseppa Pistritto; Daniela Trisciuoglio; Claudia Ceci; Alessia Garufi; Gabriella D'Orazi
Journal:  Aging (Albany NY)       Date:  2016-04       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.